3P Biopharmaceuticals is a leading CDMO specialized in the process development and GMP manufacturing of biopharmaceuticals 3P Biopharmaceuticals is a leading Contract Development and Manufacturing Organization (CDMO) specialized in the process development and manufacturing of biopharmaceuticals through mammalian, microbial and yeast expression systems. 3P offers solutions at all developmental stages: from initial steps to analytics development, preclinical and clinical phases, and commercial production. Established in 2006 near Pamplona, Spain, the company provides a comprehensive service to a wide range of customers located in Europe, North America, Australia and Asia.
Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital’s team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million.
Commentaires